From eligibility to CDx: developing and implementing effective biomarker strategies for Immuno-oncology trials

Presented at Biomarkers World Congress and Diagnostics on May 18, 2016, this presentation highlights the challenges immuno-oncology trials face. Scientists from Q2 Solutions discuss how they have engaged pharma and focused critical tools – including anatomic pathology, flow cytometry, genomics and biomarker strategies – to address these challenges. 

Download the presentation to learn about these tools as well as how this knowledge was leveraged to facilitate transitioning to companion diagnostic development.

Patrice Hugo, Ph.D., Chief Scientific Officer
Patrick Hurban, Ph.D., Senior Director and Global Head, Genomic Development/Esoteric Assays